Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02271711|
Recruitment Status : Completed
First Posted : October 22, 2014
Last Update Posted : September 2, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Recurrent Childhood Medulloblastoma Recurrent Ependymoma Recurrent Medulloblastoma||Other: Laboratory Biomarker Analysis Biological: Natural Killer Cell Therapy||Phase 1|
I. To establish the safety, feasibility, efficacy, and maximum tolerated dose (MTD) of administering autologous natural killer (NK) cells that have been propagated ex vivo with artificial antigen-presenting cells (aAPC) and administered directly into the ventricle in recurrent /refractory malignant posterior fossa tumors.
I. To assess the antitumor activity based on imaging and cytology of autologous NK cell locoregional administration directly into the lateral or fourth ventricle.
II. To determine the persistence of adoptively-transferred expanded NK cells (as performed with excess NK cells, via optional correlative studies).
III. Determine the immunophenotype and function of expanded NK cells. IV. Determine the overall response of medulloblastoma to NK-cell therapy. V. Correlate NK cell persistence, phenotype, and function with overall response.
OUTLINE: This is a dose-escalation study.
Patients receive autologous expanded NK cells intravenously (IV) into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
After completion of study treatment, patients are followed up within 30 days.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||12 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase I Study of Intraventricular Infusions of Autologous Ex Vivo-Expanded NK Cells in Children With Recurrent/Refractory Malignant Posterior Fossa Tumors of the Central Nervous System. NOAH's (New Opportunity, Advancing Hope) Protocol|
|Actual Study Start Date :||March 17, 2015|
|Actual Primary Completion Date :||August 28, 2020|
|Actual Study Completion Date :||August 28, 2020|
Experimental: Treatment (autologous ex vivo-expanded NK cells)
Patients receive autologous expanded NK cells IV into the ventricle over 3 minutes once weekly on weeks 1-3. Treatment repeats every 4 weeks for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression may continue treatment at the discretion of the treating physician if pseudo-progression or benefit of slowed progression is suspected.
Other: Laboratory Biomarker Analysis
Biological: Natural Killer Cell Therapy
Given autologous ex-vivo expanded NK cells IV
- Maximum tolerated dose (MTD) of natural killer (NK) cells [ Time Frame: 4 weeks ]Defined as the highest dose studied in which 6 patients have been treated at most 1 patient with dose limiting toxicities are observed. Toxicities will be summarized by tabulation in terms of type, grade and attribution for each dose level of each group of patients studied at the end of the trial.
- Activation status of NK cells [ Time Frame: Up to 30 days after the last infusion in course 3 ]Determined by flow-based activation assay determining cluster of differentiation (CD)107a expression of NK cells in response to standardized targets.
- Persistence of NK cells [ Time Frame: Up to 30 days after the last infusion in course 3 ]Peripheral blood and cerebrospinal fluid (CSF) will be obtained before therapy, during the NK cell treatment period, and after NK cell treatment.
- Function of NK cells [ Time Frame: Up to 30 days after the last infusion in course 3 ]Assessed by cell lysis of standardized targets.
- Response of medulloblastoma to NK cells [ Time Frame: Up to 30 days after the last infusion in course 3 ]Antitumor activity will be described for each group of patients based on imaging and cytology. Clinical response will be correlated with NK cell persistence in vivo, cytokine levels, and expression of activation markers.
- Feasibility of NK cell manufacturing [ Time Frame: Up to 12 weeks ]If analysis shows < 50% successful product generation after at least six patients have been enrolled, the study will be temporarily stopped to address possible changes in the manufacturing process.
- Feasibility of delivering NK cells [ Time Frame: Up to 12 weeks ]Therapy will be considered feasible if at least 2/3 of subjects treated receive at least 21 of the planned 27 NK cell infusions.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||up to 21 Years (Child, Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Diagnosis: patients with recurrent/refractory medulloblastoma (MB), atypical teratoid (AT)/rhabdoid tumors (RT) or ependymoma involving the brain and/or spine at original diagnosis or relapse; they must have histological verification at diagnosis and/or relapse; patient must have presented with these tumors in the posterior fossa (PF) or relapsed in the PF
- Patient must have either measurable or evaluable tumor
- Presence of or determined by neurosurgery to be a candidate for an implanted catheter in the ventricles to receive NK cell infusion
- Life expectancy of at least 12 weeks in opinion of principal investigator (PI) and/or designee
- Lansky score of 50 or greater if =<16 years of age or a Karnofsky score of 50 or greater if > 16 years of age (NOTE: patients who are unable to walk because of paralysis, but who are in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score)
- Neurologic deficits must have been relatively stable for a minimum of 1 week prior to study enrollment
- Patients must have recovered from the acute toxic effects of all prior anticancer chemotherapy
- Patient must be 4 weeks off any palliative radiation or craniospinal radiation
- Absolute neutrophil count (ANC) of >= 1000/uL
- Platelet count of >= 30,000
- Hemoglobin of >= 9.0 g/dl
- Patients with a seizure disorder may be enrolled if well-controlled and on non-enzyme inducing anticonvulsants
- Patient or patient's legal representative, parent(s), or guardian able to provide written informed consent
- Enrolled in another treatment protocol
- Evidence of untreated infection
- Extra-cranial metastasis
- Chronic corticosteroid dependence (except replacement therapy)
- Extensive disease, disease location, and/or co-morbid condition that the PI or designee considers unsafe for surgical intervention of NK cell infusion
- Pregnant or lactating women
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02271711
|United States, Texas|
|M D Anderson Cancer Center|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Soumen Khatua||M.D. Anderson Cancer Center|
|Responsible Party:||M.D. Anderson Cancer Center|
|Other Study ID Numbers:||
NCI-2014-02677 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2013-0765 ( Other Identifier: M D Anderson Cancer Center )
P30CA016672 ( U.S. NIH Grant/Contract )
|First Posted:||October 22, 2014 Key Record Dates|
|Last Update Posted:||September 2, 2020|
|Last Verified:||August 2020|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neuroectodermal Tumors, Primitive